CACrown ArchivesThe cinema collection
Menu
Research dossier · Science & Nature

Canagliflozin

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 16, 2026
Entity authorityQ5030940
Source-derived summary

Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.

Common side effects include vaginal yeast infections, nausea, constipation, and urinary tract infections. Serious side effects may include low blood sugar, Fournier's gangrene, leg amputation, kidney problems, high blood potassium, and low blood pressure. Diabetic ketoacidosis may occur despite nearly normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by increasing the amount of glucose lost in the urine.

Editorial summary

The public source identifies “Canagliflozin” as chemical compound. This brief keeps that definition visible, then builds a research path around Canagliflozin, chemical and compound.

Editorial reviewA practical orientation to terminology and classification, particularly when read beside dated observations, specimens or technical literature. The current 110-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Canagliflozin, chemical and compound providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Canagliflozin”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Aug 16, 2026. The linked authority identifier is Q5030940. None of the 0 selected statements returned an explicit reference.

Critical limits

Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Canagliflozin”, its source revision and the description used here.
  2. Expand the search: follow Canagliflozin primary sources, Canagliflozin archive and Canagliflozin research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Canagliflozin”?
  2. Which observation, specimen, dataset or publication supports the account?
  3. Has classification or technical consensus changed since the cited source?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from Canagliflozin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.